The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

Drugmakers offer “copay assistance programs” to help people afford expensive medicines. But health insurers are milking these ...

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.

DUBLIN, IE / ACCESS Newswire / February 6, 2025 / Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a ...

ClariMed, Inc., the premier human-centered medical device development and regulatory services company, today announced the ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The Local Content and Government Procurement Authority (LCGPA) announced on Feb. 6 the first batch of products eligible for ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...

The company expects 2025 adjusted profit to be in the range of $8.15 to $8.35 per share, compared with the average of ...

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...